Delayed progression to AIDS in volunteers treated with long-term HIV-1 Immunogen (REMUNE®) therapy in Thailand

HIV Medicine

Volumn 5, Issue 5, 2004, Pages 317-325

  Chantratita, W ^a   Sukeepaisarncharoen, W ^b   Chandeying, V ^c   Kulpradist, S ^d   Na Ayudhtaya, B Israngkura ^e   Rugpao, S ^f   Sirawaraporn, W ^g   Boonshuyar, C ^g   Churdboonchart, Vina ^g,h  

^a MAHIDOL UNIVERSITY   (Thailand)

^b KHON KAEN UNIVERSITY   (Thailand)

^c PRINCE OF SONGKLA UNIVERSITY   (Thailand)

^d NAVAMINDRADHIRAJ UNIVERSITY   (Thailand)

^e PRAMONGKUTKLAO HOSPITAL   (Thailand)

^f CHIANG MAI UNIVERSITY   (Thailand)

^g MAHIDOL UNIVERSITY   (Thailand)

^h Trinity Medical Group   (United States)

Author keywords

Delaying antiretroviral drug initiation; Drug resistance; Immune based therapy; Progression to AIDS rate

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IMMUNOTHERAPY; INFECTION PREVENTION; LONG TERM CARE; LYMPHOCYTE COUNT; MULTICENTER STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; T LYMPHOCYTE; THAILAND; TREATMENT OUTCOME; VIRUS LOAD; VOLUNTEER;

AIDS VACCINES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BODY WEIGHT; DISEASE PROGRESSION; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; LYMPHOCYTE COUNT; THAILAND; VIRAL LOAD;

EID: 4644372686     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2004.00230.x     Document Type: Article

References (27)

1. Rosenthal E. AIDS patients in China lack effective treatment. The New York Times (International Section) 12 November 2001: A1.
2. Swarns RLA. South African hospital fights AIDS and despair. The New York Times (International Section) 26 November 2001: A1.
3. Panel on Clinical Practice for Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. http://www.aidsinfo.nih.gov/guidelines 2004.
4. The British HIV Association. Guidelines for the Treatment of HIV-Infected Adults with Antiretroviral Therapy. London, British HIV Association (BHIVA), 2003. http://www.bhiva.org/guidelines/2003/hiv/introduction.html.
5. Hogg RS, Yip B, Chan KJ et al. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. J Am Med Assoc 2000; 286: 2568-2577.
6. Limsuwan A, Churdboonchart V, Moss RB et al. Safety and immunogenicity of REMUNE in HIV-infected Thai subjects. Vaccine 1998; 16: 142-149.
7. Churdboonchart V, Moss RB, Sirawaraporn W et al. Effect of HIV-specific immune-based therapy in subjects infected with HIV-1 subtype E in Thailand. AIDS 1998; 12: 1521-1527.
8. Churdboonchart V, Sakondhavat C, Kulpradist S et al. A double-blind, adjuvant-controlled trial of human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) monotherapy in asymptomatic, HIV-1-infected Thai subjects with CD4-cell counts of > 300. Clin Diag Lab Immunol 2000; 7: 728-733.
9. Sukeepaisarncharoen W, Churdboonchart V, Kulpradist S et al. Long-term follow-up of HIV-1 infected Thai subjects immunized with Remune monotherapy. HIV Clin Trials 2001; 2: 391-398.
10. Prior CP, Gore R, Harter J et al. Inactivation and purification of human immunodeficiency virus-1 as antigen for the treatment of HIV-1 infection. Biopharmacology 1996; 9: 22-34.
11. Prior C, Bay P, Ebert B et al. Process development for the manufacture of inactivated HIV-1. Pharmaceut Technol 1995; 19: 30-52.
12. Choi DJ, Dube S, Spicer TP et al. HIV type 1 isolate Z321, the strain used to make a therapeutic HIV type 1 immunogen, is intersubtype recombinant. AIDS Res Hum Retroviruses 1997; 13: 357-30.
13. Young NL, Ponglertnapakorn P, Shaffer N et al. Clinical field site evaluation of the FACSCount for absolute CD3 +, CD3 + CD4 +, and CD3 + CD8 + cell count determinations in Thailand. Clin Diagn Lab Immunol 1997; 4: 783-786.
14. Revets H, Marissens D, De Wit S et al. Comparative Evaluation of NASBA HIV-1 RNA QT, AMPLICORE-HIV Monitor, and QUANTIPLEX HIV RNA Assay, three methods for quantification of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 1996; 34: 1058-1064.
15. Van Buul C, Cuypers H, Lelle P et al. The NucliSens™ Extractor for automated nucleic acid isolation. Infusionstherapie Transfusionsmed 1998; 25: 147-151.
16. Boom R, Sol CJA, Salimans MMM et al. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990; 28: 495-503.
17. Coste J, Montes B, Reynes J et al. Comparative evaluation of three assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma. J Med Virol 1996; 50: 293-302.
18. Kuritzkes DR, Grant RM, Feorino P et al. Performance characteristics of the TRUGENE HIV-1 Genotyping Kit and the Opengene DNA Sequencing System. J Clin Microbiol 2003; 41: 1594-1599.
19. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992; 41: 1-19. (http://www.cdc.gov).
20. Wannamethee SG, Sirivichayakul S, Phillips AN et al. Clinical and immunological features of human immunodeficiency virus infection in patients from Bangkok, Thailand. Int J Epidemiol 1998; 27: 289-295.
21. Sirivichayakul S, Phanuphak P, Hanvanich M et al. Clinical correlation of the immunological markers of HIV infection in individuals from Thailand. AIDS 1992; 6: 393-397.
22. Kilmarx PH, Limpakarnjanarat K, Kaewkungwal J et al. Disease progression and survival with human immunodeficiency virus type 1 subtype E infection among female sex workers in Thailand. J Infect Dis 2000; 181: 1598-1606.
23. Fernández-Cruz E, Muñoz-Fernandez MA, Navarro J et al. Randomized control phase II trial evaluating HIV-1 immunogen administered to patients with HIV-1 chronic infection having 300 to 700 cells/ml CD4 cell counts: data from a recently unblinded study. Proceedings of the First IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires, Argentina, 8-11 July 2001 [Abstract LB-P17].
24. 6/L CD4 cells counts. J Am Med Assoc 2000; 284: 2193-2202.
25. Turner JL, Kostman JR, Aquino A et al. The effects of an HIV-1 immunogen (REMUNE™) on viral load, CD4 cell counts, and HIV-specific immunity in a double-blind, randomized, adjuvant-controlled subset study in HIV infected subjects regardless of concomitant antiviral drugs. HIV Med 2001; 2: 68-77.
26. Poprawski D, Pitisuttitum P, Tansuphasawadikul S. Clinical presentations and outcomes of TB among HIV-positive patients. Southeast Asian J Trop Med Public Health 2000; 31 (Suppl. 1): 140-142.
27. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348: 283-291.